Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Current Assets (2017 - 2025)

Aclaris Therapeutics has reported Current Assets over the past 9 years, most recently at $96.3 million for Q4 2025.

  • Quarterly results put Current Assets at $96.3 million for Q4 2025, down 23.53% from a year ago — trailing twelve months through Dec 2025 was $96.3 million (down 23.53% YoY), and the annual figure for FY2025 was $96.3 million, down 23.53%.
  • Current Assets for Q4 2025 was $96.3 million at Aclaris Therapeutics, down from $100.6 million in the prior quarter.
  • Over the last five years, Current Assets for ACRS hit a ceiling of $259.4 million in Q2 2022 and a floor of $96.3 million in Q4 2025.
  • Median Current Assets over the past 5 years was $133.7 million (2021), compared with a mean of $160.8 million.
  • Biggest five-year swings in Current Assets: surged 256.62% in 2021 and later plummeted 52.03% in 2023.
  • Aclaris Therapeutics' Current Assets stood at $205.0 million in 2021, then rose by 12.93% to $231.6 million in 2022, then tumbled by 44.35% to $128.9 million in 2023, then dropped by 2.25% to $126.0 million in 2024, then fell by 23.53% to $96.3 million in 2025.
  • The last three reported values for Current Assets were $96.3 million (Q4 2025), $100.6 million (Q3 2025), and $104.2 million (Q2 2025) per Business Quant data.